Need Support?
Histocompatibility billing breaks from standard lab medicine: solid organ transplant HLA services flow through the hospital’s organ acquisition cost center on a reasonable-cost basis via the Medicare cost report, while stem cell HLA typing bundles into DRG/APC payment. Get the pathway wrong, and a clinically necessary test yields zero reimbursement. Generalist billers rarely grasp this distinction; the loss compounds until a cost report reconciliation reveals it.
Standalone CPT Billing of Solid Organ Transplant HLA Services
Living Donor Identity & Billing Errors
Under-Captured Antibody Interpretation Revenue
Chimerism Testing Frequency & Timing Denials
Kidney Paired Donation Cross-Hospital Billing Errors
Molecular HLA Class I and II typing at low resolution/antigen equivalent level (81370) through high-resolution allele-level typing of individual loci (81371-81383), used for transplant donor-recipient matching and unrelated donor registry searches.
Resolution level billed must match what was actually performed and reported --- billing a high-resolution code when only antigen-level typing was completed is a frequent and easily audited discrepancy.
Complement-dependent cytotoxicity crossmatch, with (86805) and without (86806) antihuman globulin enhancement, and flow cytometry crossmatch for T-cell and B-cell reactivity (86825, 86826), used to detect preformed donor-specific antibodies before transplant.
The specific crossmatch method performed, cytotoxicity versus flow cytometry, must match the CPT code billed exactly, and the number of donor-recipient pairs tested must be reflected in the units submitted.
Cytotoxic percent reactive antibody screening (86807, 86808) and solid phase single antigen bead assays used to identify and characterize specific anti-HLA antibodies (86828-86830), central to calculating a patient's sensitization level while awaiting transplant.
Single antigen bead testing generates a large volume of interpretive data per specimen --- undercounting the antibody specificities actually identified and reported is one of the most common sources of uncollected revenue in this category.
Ongoing post-transplant surveillance for donor-specific antibodies using solid phase assays, combined with molecular donor and recipient typing data to support virtual crossmatch determinations without requiring a live donor specimen.
Virtual crossmatch relies on precise mapping of molecular typing results to UNOS antigen equivalents --- documentation gaps in that mapping process can affect both clinical decision-making and the defensibility of the billed interpretation.
Short tandem repeat-based chimerism analysis without cell selection (81265) and with cell subset selection (81266), used after allogeneic stem cell transplant to monitor donor cell engraftment and detect early signs of graft failure or relapse.
Chimerism testing tied to a documented clinical indication, such as monitoring for relapse or graft failure, is far less likely to be denied than testing billed on a fixed post-transplant calendar schedule without that link.
Targeted HLA allele testing performed for non-transplant clinical indications, including HLA-B27 for suspected ankylosing spondylitis and related spondyloarthropathies, and HLA-DQ2/DQ8 testing to support or exclude a celiac disease diagnosis.
These tests use the same molecular typing CPT codes as transplant HLA typing but carry entirely different medical necessity documentation --- claims must clearly reflect the non-transplant clinical indication to avoid confusion with transplant-related billing.
HLA typing, crossmatch, and antibody testing performed in connection with a covered solid organ transplant (kidney, heart, lung, liver, pancreas, intestinal), captured as an organ acquisition cost rather than billed as a standalone laboratory claim.
Medicare denies standalone CPT claims for these services outright when tied to a covered solid organ transplant --- the cost must instead be captured through the transplant hospital's organ acquisition cost center and reported on the Medicare cost report.
High-resolution HLA typing and unrelated donor registry search support for allogeneic stem cell and bone marrow transplant, including the molecular-to-antigen mapping required for national registry matching algorithms.
HLA typing for an allogeneic stem cell transplant is bundled into the MS-DRG payment for inpatient transplants or the OPPS APC payment for outpatient transplants --- it is not separately payable, and billing it as a standalone claim results in denial.
TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.
Complete payer enrollment, CLIA certification management, and network participation setup across all insurance carriers. TransLabs manages every credentialing detail so that your laboratory gets paid in-network from day one without any administrative delays.
Real-time insurance verification, benefits investigation, and prior auth completed before specimen processing begins. Confirming coverage upfront eliminates preventable denials and protects your lab from unexpected reimbursement failures.
Patient registration, appointment coordination, insurance verification, and customer service excellence managed by experienced laboratory billing professionals. A well-run front office reduces downstream billing errors and creates a better experience.
TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.
HLA typing, crossmatch, and antibody testing performed for a covered solid organ transplant must be captured as an organ acquisition cost and reported on the transplant hospital's Medicare cost report, not billed as a standalone laboratory claim. Standalone CPT claims for these services in a solid organ transplant context are denied automatically. TransLabs routes these services correctly from the start and supports the documentation your finance team needs for cost report preparation.
Transplant hospitals must establish separate standard acquisition charges for living and deceased donor organs, reflecting the average reasonable and necessary costs of organ procurement, including histocompatibility testing. TransLabs ensures histocompatibility testing costs are properly captured and categorized to support accurate SAC calculation.
HLA typing performed in connection with an allogeneic stem cell transplant is bundled into the MS-DRG payment for inpatient transplants or the OPPS APC payment for outpatient transplants, with no separate payment available. TransLabs confirms bundling status before a claim is submitted to prevent an automatic denial.
Living donor complications and related testing costs are billed under the transplant recipient's Medicare Beneficiary Identifier, with no deductible or coinsurance liability to the donor. TransLabs verifies the correct beneficiary identifier is used on every living donor-related claim.
When a donor is evaluated at one transplant hospital and matched to a recipient at another through a paired exchange program, specific CMS-compliant billing sequences govern which hospital bills which costs and when. TransLabs applies these protocols correctly to prevent both reimbursement gaps and cost report inconsistencies.
Histocompatibility labs must accurately map molecular HLA typing results to UNOS antigen equivalents for entry into the national organ matching system, a process with real financial and clinical stakes for accurate donor-recipient matching. TransLabs supports documentation practices that keep this mapping process defensible.
Organ acquisition cost centers have been repeatedly audited by the OIG for cost-shifting between pre- and post-transplant activities and for improperly allocated staff time. TransLabs builds documentation practices around these known audit risk patterns to support your transplant program's compliance posture.
Schedule a call with our histocompatibility billing specialist. We’ll review your billing pathway accuracy, organ acquisition cost documentation, non-transplant testing claims, and A/R days.
Dedicated billing specialist assigned to your lab or transplant program
Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers
Uncover your top 3 revenue leaks (standalone billing errors, documentation gaps, timing denials)
Custom strategy tailored to your test menu and LIS/billing software
Live in 24 hours with no contracts and no upfront fees
Pay only a percentage of what we collect for you